Syros Pharmaceuticals Stock Filter Stocks by Fundamentals
| SYRS Stock | USD 0.27 0.02 8.00% |
Syros Pharmaceuticals fundamentals help investors to digest information that contributes to Syros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syros Stock. The fundamental analysis module provides a way to measure Syros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syros Pharmaceuticals stock.
Syros | Shares Owned by Institutions |
Syros Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Syros Pharmaceuticals from analyzing Syros Pharmaceuticals' financial statements. These drivers represent accounts that assess Syros Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Syros Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 277.9M | 499.7M | 203.9M | 45.3M | 220.7M | 141.1M | |
| Enterprise Value | 262.4M | 391.9M | 176.8M | (58.5M) | 143.2M | 99.6M |
Syros Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Syros Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Syros Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Syros Pharmaceuticals' value.| Shares | Ubs O'connor Llc | 2024-09-30 | 359.3 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 313 K | Walleye Trading Advisors, Llc | 2024-06-30 | 285.8 K | Goldman Sachs Group Inc | 2024-06-30 | 262.4 K | Blackrock Inc | 2024-06-30 | 259.2 K | Omega Fund Management Llc | 2024-09-30 | 251.3 K | Geode Capital Management, Llc | 2024-09-30 | 204.7 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 160.4 K | Exome Asset Management Llc | 2024-06-30 | 159.2 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 2.8 M | Artal Group S A | 2024-06-30 | 2.5 M |
Syros Fundamentals
| Return On Equity | -7.77 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (288.92) % | ||||
| Current Valuation | 8.68 M | ||||
| Shares Outstanding | 26.83 M | ||||
| Shares Owned By Insiders | 1.37 % | ||||
| Shares Owned By Institutions | 75.58 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Earning | (7.92) X | ||||
| Price To Book | 10.65 X | ||||
| Price To Sales | 17.44 X | ||||
| Revenue | 9.94 M | ||||
| Gross Profit | 14.88 M | ||||
| EBITDA | (157.19 M) | ||||
| Net Income | (164.57 M) | ||||
| Cash And Equivalents | 244.48 M | ||||
| Cash Per Share | 12.09 X | ||||
| Total Debt | 62.08 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 6.57 X | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (109.71 M) | ||||
| Short Ratio | 1.38 X | ||||
| Earnings Per Share | (3.07) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 68 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 6.73 M | ||||
| Total Asset | 168.17 M | ||||
| Retained Earnings | (722.81 M) | ||||
| Working Capital | 108.3 M | ||||
| Current Asset | 85.51 M | ||||
| Current Liabilities | 9.57 M | ||||
| Net Asset | 168.17 M |
About Syros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.